Nci cohort consortium projects electricity 2pm mp3


Bladder cancer is the 7th most common cancer worldwide, with an estimated 260,000 new cases diagnosed annually in men and 76,000 in women. The strongest risk factors for bladder cancer are cigarette smoking and occupational exposure to carcinogens. Despite extensive research by many individual studies, it remains unclear whether bladder cancer is related to other modifiable factors such as NSAID use, diet, alcohol and other beverage consumption, overweight and obesity and, for women, reproductive history, oral contraceptive use and hormone therapy use. The main objective of this project will be to use pooled prospective cohort data to assess associations with bladder cancer risk for predominantly modifiable lifestyle factors for which findings to date have been inconclusive. Another goal will be to carry out gene-environment interaction (GxE) analyses in studies that have already scanned samples for GWAS. gas works park fireworks Finally, there is also the possibility of scanning at NCI additional samples from all cohorts, including those that haven’t participated in previous GWAS.

Within the framework of the NCI-sponsored Cohort Consortium, investigators from 12 prospective epidemiologic cohorts formed the Pancreatic Cancer Cohort Consortium in 2006. The group’s first study, also known as "PanScan I," involved a genome-wide association study (GWAS) of common genetic variants to identify markers of susceptibility to pancreatic cancer. In 2007, the study was expanded to include 8 case-control studies (PanScan II). PanScan I and II led to the discovery of four novel regions in the genome associated with risk for pancreatic adenocarcinoma.

The third phase of PanScan (PanScan III), will study recently identified incident pancreatic cancer cases and controls drawn from 14 cohorts from the NCI Cohort Consortium, including the 10 prospective cohorts who participated in PanScan I and II, and four newly joined cohorts. Therefore, PanScan III will include approximately 2,400 additional cases for genome-wide scanning. In a replication study, PanScan III investigators will genotype the top 20-50 loci from the GWAS. gas efficient cars 2010 A joint analysis of the newly scanned cases will be conducted with cases from PanScan I and II to identify novel regions of the genome associated with pancreatic cancer susceptibility. With the larger sample size (about 6,200 cases and 13,900 controls), it is anticipated that the PanScan III study will identify new genetic risk variants for etiology. See publications here.

Gastric cancer is the fifth most common type of cancer and the third leading cause of cancer deaths worldwide. It is critical to develop novel biomarkers for gastric cancer prevention. Serum autoantibodies (AAbs), which result from humoral immune response to aberrantly expressed, mutated or post-translationally modified proteins, have been proposed as promising biomarker candidates. Several serum antigen biomarkers have been identified for gastric cancer. Evidence suggests that AAbs can be detected at premalignant stages prior to diagnosis; however, no studies have investigated them as using samples collected from cases prior to diagnosis. In addition, many studies only measured a limited set of candidate autoantibodies. Recent progresses in the development of antibody detection technologies like protein microarrays and immuno-bead assays make it possible to detect multiple autoantibodies simultaneously with sufficient reproducibility. gas kinetic energy formula We aim to identify a panel of autoantibodies that can be measured in pre-diagnostic serum samples to differentiate gastric cases from controls.

The African American Working Group of the NCI Cohort Consortium was formed in 2011 when seven large epidemiology cohorts, each with at least 10,000 African American participants, joined to look at anthropometric measures in relation to mortality in African Americans. The original goals of the Working Group were to assess the relation of body mass index to all-cause, cancer, and CVD mortality, and then pancreas cancer and multiple myeloma, in African American men and women. Limited NCI extramural funds supported data harmonization and preparation of analysis datasets. nyc electricity cost Since then the Working Group’s objectives have expanded to broadly examine determinants of cancer risk and outcome among African Americans. The group now provides a platform for development of new collaborative research leveraging existing data and resources in the Cohort Consortium. The seven cohorts participating in this project are: NIH-AARP; Adventist Health Study 2; Black Women’s Health Study; Cancer Prevention Study II; Multiethnic Cohort Study; Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; and Southern Community Cohort Study. View publications from this project.

With the completion of GWAS for breast cancer and prostate cancers in aggregate, important questions remain that the BPC3 is uniquely positioned to answer. Estrogen receptor negative (ER-) breast cancers have specific epidemiologic characteristics and greater lethality, but the current generation of scans is underpowered to discover gene variants associated with these tumors. Aggressive forms of prostate cancer, characterized by extraprostatic extension (Stage C/D) or high histologic grade (Gleason score 8+), differ epidemiologically from the vastly more common indolent forms of prostate cancer and are of the greatest clinical importance, but again the current scans are underpowered to discover associated genetic determinants. No single study is likely to have enough cases of these cancer subtypes to perform a GWAS. By pooling cases across the BPC3 studies, the investigators can achieve adequate power to discover genetic variation that gives rise to these important clinical subtypes. See publications here.

This project, initiated in 2007, is a nested case-control study that analyzed the association between 25(OH)D (serum vitamin D concentrations) and the development of seven rarer cancers: endometrial, esophageal, stomach, ovarian, pancreatic, and kidney cancers, and non-Hodgkin lymphoma (NHL). The study involved 10 cohorts, and participants’ vitamin D levels were measured in serum collected before the development of cancer. Study findings do not support the hypothesis that circulating 25(OH) D concentrations are associated with a reduced risk of developing any of these seven rarer cancers. The results were published in 2010.

Investigators interested in proposing a project should fill out the form below and e-mail the completed form to Nonye Harvey, NCI Cohort Consortium Coordinator. up electricity bill payment online The deadline for submitting new proposals is the 1st of each month, with Steering Committee review within one month of receipt. Although investigators can submit proposals at any given time throughout the year, they will not be reviewed until after the next deadline closest to the time of submission. For more information on the evaluation criteria for pooling projects, see the link below. Questions about the proposal process should be sent to